The present invention relates to a pharmaceutical antiretroviral composition comprising lamivudine festinavir and nevirapine to a process for preparing such a composition and to the use of such a composition for the treatment and/or prophylaxis of diseases caused by retroviruses especially acquired immune deficiency syndrome or an HIV infection.

The present invention relates to a pharmaceutical antiretro viral composition comprising (i) a nucleoside reverse-transcriptase inhibitor selected from lamivudine and emtricitabine (ii) extended release nevirapine and (iii) tenofovir; a process for preparing such composition and the use of such composition in medicine particularly for the prophylaxis and/or treatment of diseases caused by retroviruses.

The invention relates to an extended release pharmaceutical composition comprising nevirapine.

The present invention relates to a pharmaceutical antiretroviral composition comprising lamivudine festinavir and nevirapine to a process for preparing such a composition and to the use of such a composition for the treatment and/or prophylaxis of diseases caused by retroviruses especially acquired immune deficiency syndrome or an HIV infection.

FIELD: biotechnologies.SUBSTANCE: invention relates to new non-nucleoside inhibitors of virus reproduction representing pyrimidine derivatives of benzophenon: 1-[2-(2- benzoylphenoxy)ethyl]uracyls corresponding to a structural formula:where: R=H CH F Br; R=H CH.EFFECT: new compounds do not contain additional substitutes in aromatic nuclei of a benzophenone fragment and show anti-HIV-1 activity in vitro which exceeds activity of nevirapine and matches activity of efavirenz.3 tbl 3 ex

The present invention is directed to extended release pharmaceutical compositions comprising nevirapine a release control polymer/ material and one or more pharmaceutically acceptable excipients process for its preparation and use in the treatment of HIV-1 infection in adults.